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Abstract
Background: Advances in the management of retinal diseases have been fast-paced as new treatments become
available, resulting in increasing numbers of patients receiving treatment in hospital retinal services. These patients
require frequent and long-term follow-up and repeated treatments, resulting in increased pressure on clinical
workloads. Due to limited clinic capacity, many National Health Service (NHS) clinics are failing to maintain
recommended follow-up intervals for patients receiving care. As such, clear and robust, long term retinal service
models are required to assess and respond to the needs of local populations, both currently and in the future.
Methods: A discrete event simulation (DES) tool was developed to facilitate the improvement of retinal services by
identifying efficiencies and cost savings within the pathway of care. For a mid-size hospital in England serving a
population of over 500,000, we used 36 months of patient level data in conjunction with statistical forecasting and
simulation to predict the impact of making changes within the service.
Results: A simulation of increased demand and a potential solution of the ‘Treat and Extend’ (T&E) regimen which
is reported to result in better outcomes, in combination with virtual clinics which improve quality, effectiveness and
productivity and thus increase capacity is presented. Without the virtual clinic, where T&E is implemented along
with the current service, we notice a sharp increase in the number of follow-ups, number of Anti-VEGF injections,
and utilisation of resources. In the case of combining T&E with virtual clinics, there is a negligible (almost 0%)
impact on utilisation of resources.
Conclusions: Expansion of services to accommodate increasing number of patients seen and treated in retinal
services is feasible with service re-organisation. It is inevitable that some form of initial investment is required to
implement service expansion through T&E and virtual clinics. However, modelling with DES indicates that such
investment is outweighed by cost reductions in the long term as more patients receive optimal treatment and
retain vision with better outcomes. The model also shows that the service will experience an average of 10%
increase in surplus capacity.
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Background
Hospital Eye Services in the United Kingdom (UK) National
Health Service (NHS) have consistently had a low profile,
despite providing a high volume of work. They account for
nearly one in ten hospital outpatient appointments, as the
second highest demand specialty with 5.95 million clinic at-
tendances in 2009/10 in England and 7–8% of all surgical
operations performed by the NHS. Furthermore, demand
has risen by 25% over 7 years [1].
Amongst all ophthalmology clinic attendances, retinal
vascular diseases are a leading cause of sight loss. The
three specific causes of such visual loss are age related
macular degeneration (AMD), diabetic retinopathy (DR),
and retinal vascular occlusions (RVO). These conditions
are of particular interest as their prevalence is rising in an
increasingly ageing population, as AMD and RVO are as-
sociated with increasing age, and diabetes mellitus, occurs
more frequently. AMD as a serious macular disorder,
which is forecasted to rise from 513,000 in 2010 to
679,000 in 2020, an increase of 32% in just 10 years [2].
These patients may require monthly outpatient visits and
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treatments until disease stability is achieved, followed by
implementation of various regimens including pro re nata
(PRN) treatment, fixed interval dosing being the most
popular until recently [3–6]. Emerging evidence suggests
that outcomes are better with Treat and Extend (T&E)
regimen [7–11]. However, these treatments and regimen
are resource intensive, and require multi-disciplinary
teams including photographers, optometrists, specialist
nurses, and pharmacists, in addition to the
ophthalmologist.
Given the frequency of treatment and monitoring
visits (usually monthly), combined with increasing de-
mand for services where the number of treatable pa-
tients potentially suitable for treatment have risen
markedly, many NHS ophthalmology clinics are cur-
rently running at 100% capacity and some are failing to
maintain the recommended follow-up and re-treatment
intervals. Most of these clinics which are running at
maximum capacity may not have scope for further ex-
pansion. They cannot cope with the current patient
numbers, let alone allow for future increases in patient
numbers.
It is clear that robust and long term retinal service
delivery modelling is required across NHS clinics in
order to determine the current and future needs of
local populations, so that there is no future com-
promise in the standard of service provision, includ-
ing follow-up (FU) intervals and quality of
intravitreal treatment administration. Amoaku et al.
(2012) [12] produced a comprehensive list of changes
that can be made in order to meet existing demand and
needs of patients with limited resources and capacity. In
that publication, the authors shared a number of service
re-design case studies, e.g., virtual clinics. Virtual clinics
usually consist of non-mydriatic photos of the optic disc,
visual fields, and visual acuity measurements carried out
by a technician, stored, and later reviewed by an Ophthal-
mologist [13]. A virtual clinic can be within a hospital set-
ting or in a location within the community. If it is located
in the community then patients are shifted from a hospital
setting where treatment (or a follow-up routine appoint-
ment) is provided out in the community, thus releasing
the pressure on hospitals. A number of other authors have
presented similar models (including virtual clinics) of
dealing with capacity constraints [14–18].
Despite these efforts, the quantifiable impact of
re-designing retinal services has never been studied.
Whether planned service re-design will actually result in
increased capacity, and if so how much cost improve-
ment will result remains unknown. Furthermore, it is
unknown as to how a change in one area of the service
will impact on resources in another including activity
(new and FU appointments), resource utilisation and
costing and revenue.
The aims of this study are therefore: 1) to develop a
discrete event simulation (DES) model, which captures
the retinal service treatment pathways and service
re-designs including virtual clinics; 2) Second, to deter-
mine possible and realistic policies, which could be im-
plemented with regard to an increased use of virtual
clinics combined with a new treatment regimen (known
as treat and extend), and how these would affect hospital
based treatment; 3) to evaluate the impact of the imple-
mentation of this service re-design on a number of oper-
ational and cost performance indicators relevant to the
delivery of retinal services. This should provide an indi-
cation of the feasibility and scale of improvement, both
operationally and patient outcomes, and allow health
managers to make informed decisions with regard to the
best ways to reconfigure the delivery of retinal services
in the UK. This study was based on the retinal service of
a mid-sized NHS hospital Trust in England.
Methods
A unique version of a discrete event simulation model
was developed for Cambridge University Hospitals NHS
Foundation Trust in three stages. Firstly, the Trust’s pa-
tient level ophthalmology data was anonymised and ana-
lysed in greater detail. Secondly, the structure of the
Trust’s intravitreal injection service as delivered at the
time (mainly a prn regime) was established using man-
agement and clinician expertise. Finally, the combination
of both sets of analysis and statistical forecasts were en-
tered into the model. Using sophisticated statistical algo-
rithms, we forecast activity by patient type (AMD, DR
and RVO) broken down by new patients and follow-up
(FU) visits. The simulation was then ran many times giv-
ing accurate information on the next twelve months of
activity, resource utilisation and revenue/costing to pro-
vide baseline values. The baseline was then compared to
any number of other alternative methods of delivering
the intravitreal injection service. This enabled the Trust
to explore the impact of service redesign options rapidly
and with ease in order to identify the most effective
solutions.
The problem/hypothesis
In order to address the issue of increasing patient num-
bers and to demonstrate how the model could be used to
identify service efficiencies, we explored the impact on the
service by adopting the T&E regimen in combination with
virtual clinics compared to the current regime of prn de-
livery as described in the SUSTAIN Study [4, 7–10, 18].
Using real data from this hospital Trust, it was confirmed
that the service currently used the PRN regime. The
model calculated that there was an average rate of 4 injec-
tions in year 1, 3 in year 2, and 2.5 in year 3 with this re-
gime. The service would like to change their treatment
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methodology to T&E in order to improve patient out-
comes. However, this would mean an increase in the num-
ber of injections to 8, 6 and 4–5 in years 1, 2 and 3,
respectively. Analysis of the service data indicated that
there was insufficient capacity to increase the number of
injections at neutral cost without other service changes.
The adoption of virtual clinics seemed to have the impact
of reducing the number of FU appointments at the Trust.
Conceptualising retinal service patient pathway
The objective was to explore the clinic pathway in ret-
inal services in order to establish what, in the experts’
opinion, were important areas for development. The
pathway mapping consisted of structured interviews
with retinal service nurses across a number of clinics be-
tween March and August 2015. The interviewer dis-
cussed each stage of the pathway with the interviewee
taking account of the interviewee’s opinion and adjusting
the pathway in ‘real time’ as comments were made.
According to the interviews, the typical care system in
place in the NHS and elsewhere, for the diagnosis, initial
treatment and subsequent FU/treatments in patients
with eye problems comprised of a complex set of ser-
vices offered in and out of hospital. Fig. 1 shows the
inner workings of the retinal service pathway diagram-
matically. Patients were referred (first referral) to retinal
services via their General Practitioner (GP) or commu-
nity optometrist and, on a small number of occasions,
via accident and emergency (A&E) or outpatient ser-
vices. FU evaluation and treatment would subsequently
follow. Existing patients will either continue treatment
(primarily with intravitreal injections) and/or continue
with monitoring/assessment (follow-up review) as de-
scribed in SUSTAIN study [4]. To facilitate real life set-
ting, the Trust’s appointment booking system was
incorporated into the model to ensure bookings were
captured accordingly. Where a patient either cancelled
or ‘did not attend’ (DNA) re-bookings were made ac-
cording to the service rules.
Patient level data analysis and forecasting
Thirty-six months of individual patient level data was
obtained from Cambridge University Hospitals NHS
Trust (April 2013 – March 2016). Using the statistical
software R (library package forecast), a series of models
was developed to forecast activity by patient type
(nAMD, DR and RVO) broken down into “new patients”
and “FUs”. The forecasted activity was then adjusted for
population growth rates and collated to estimate future
activity for 2016–17 (12 months forecast). When the
projected activity for 2015–16 was compared with the
actual activity, forecast accuracy was in the region of
90–99%.
In addition to demand forecasting, many parameters
were estimated and their distributions were identified by
using the fitdistr package in R, such as the distribution
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Fig. 1 Conceptualised pathway for retinal service patients
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of the number of injections in years 1, 2 and 3 of treat-
ment, waiting time for the first outpatient appointment,
distribution of the number of FU assessments in each of
the 3 years. Individual patients were tracked over the
36 month period and the number of times the patient
was injected and monitored was counted within each of
the 3 years.
Model input parameters
Model inputs included staffing levels and salaries, staff
availability, staff responsibilities, treatment pathways, ar-
rivals (forecasted activity by new vs. follow-up atten-
dances), percentage of patients falling into each category
(nAMD, DR and RVO), costing of each service/drug/
staff, treatment option visit parameters, appointment
booking system parameters, clinician rota system, room/
injection bed availability and weekly clinic sessions. The
majority of input parameters were estimated through ex-
haustive analysis of patient level data, and where no data
was available literature and/or expert opinion was used.
See Additional file 1: Table S5 for the list of input
parameters.
Service re-design
Service delivery configurations involving increased use
of community services (e.g. virtual clinics) could yield ef-
ficiency gains both operationally and financially. Oper-
ationally, it reduces unnecessary hospital attendances to
ophthalmology clinics, and the need for consultations
with ophthalmology doctors and nurses. Financially,
treating patients in the community (i.e. within a virtual
clinic setting) has a significant cost advantage over treat-
ment in hospitals. The average cost of an outpatient
follow-up assessment (or routine check-up) is around
£89, whereas the same visit within a virtual clinic would
cost in the region of £30–£45 [19]. This is why increased
use of virtual clinics are welcomed by the Department of
Health and Social Care in England, and in-line with their
current policies. Virtual clinics are also welcomed by key
decision makers within ophthalmology clinics, including
service managers, consultants and senior nurses. It re-
lieves the pressure for patient’s waiting for an outpatient
appointment (first referral) and existing patients to re-
ceive frequency of treatment as recommended by the
National Institute for Health and Care Excellence
(NICE) [20]. The vast majority of research with regard
to ophthalmology clinic operations and performance
evaluation, has focused on quality of life of patients and
the effects of AMD, DR and RVO related symptoms and
social factors on the physical and psychological well-
being of patients.
The lack of research to evaluate operational and cost
performance of possible service re-designs within retinal
services warrants further investigation. The discrete event
simulation model we have developed here enables us to
experiment any combination of service re-design configu-
rations, i.e., the model is generic enough to run any set of
scenarios.
Amongst many service configurations virtual clinic is
known to be the most popular form of service re-design,
which was also requested by ophthalmology (retinal ser-
vice) managers, doctors and senior nurses. In addition to
virtual clinics we also experiment the system under a
new treatment regime. Therefore, in order to change
from the existing service utilisation of the PRN to a T&E
regime to improve patient outcomes, an increase in the
number of injections to 8, 6 and 5 in years 1, 2 and 3, re-
spectively would be required. Analysis of the service data
showed clearly that at the time there was insufficient
capacity to increase the number of injections. Projec-
tions were made as to how many appointment slots were
required in order to bridge the capacity shortfall. The
impact such a service change on activity, resource util-
isation, costing and revenue required determination.
Results
According to the patient level data the Trust had a total
of 6520 attending patients, including 17.2%, 42.3% and
40.5% are nAMD, DR and other medical retina (MR)
conditions (including 50% RVO patients, and the
remaining 50% which were non-AMD/DR/RVO related),
respectively.
Over the 3 year period of April 2013 – March 2016, a
total of 22,129 appointments were attended, of which 42%
were nAMD related (9354), 32% DR (6977) and 26% other
MRE diseases including RVO (5798) (see Table 1).
The 3295 injections for nAMD patients incurred 4851
FU assessments and a further 1208 assessments for pa-
tients who had no form of treatment (observation only).
Approximately 69% and 66% of activity for DR and MR
respectively were observation/monitoring only, and did
not require any intravitreal injections.
Table 2 shows the average number of intravitreal injec-
tions and FU assessments over the 3 year data period.
Patient level data in this study showed that patients
Table 1 Breakdown of activity by attended appointments
during April 2013 – March 2016
Activity AMD DR MR
No. of intravitreal injections 3295 425 743
No. of intravitreal injection related FU assessments 4851 599 955
No. of laser treatments N/A 315 63
No. of laser related FU assessments N/A 848 191
No. of observations 1208 4790 3846
Total 9354 6977 5798
Patients under observation refer to a group of patients who had no form of
treatment, hence under observation only
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received between 1 and 14 times in a year with signifi-
cantly lower averages. However, the model inputs uti-
lised distributions rather than these averages, for
example, the distribution for FU assessments for obser-
vations is log-normal with mean of 1.4 and standard de-
viation (SD) of 0.37. According to the data, only 1% and
19% of treated and non-treated patients, respectively are
discharged. Amongst those non-treated discharged pa-
tients, the vast majority are discharged at the end of year
1 and the discharge probability reduced dramatically
from year 2 onwards (see Table 3 for details). In the UK,
discharge from the hospital is the point at which the pa-
tient leaves the hospital and either returns home or is
transferred to another facility.
The number of patients who had no form of treatment
(ie observations only) over the data period was 5505
(Table 3). Out of this cohort the number of patients who
attended in the last 2 years and were ‘observation only’
(ie persons who had no form of treatment) in the last
6 months was 894. This group of patients were referred
to a nurse-led virtual clinic, where images are obtained
from patients in absence of the clinician. The images
were then reviewed subsequently by a clinician or other
trained personnel who made disease management deci-
sions. Extra capacity was achieved by referring 894 pa-
tients to a virtual clinic [18] in order to enable T&E
regimen to be implemented.
Table 4 displays the monthly average efficiencies that
could be achieved through service re-design as fore-
casted by the model. Column 1 figures display the ‘as is’,
or current state for the service if it were to continue un-
changed for each resource. The second column shows
the impact of introducing a virtual clinic (with no
change in current service), where 894 patients were
seen. As these patients are shifted from current setting
to the virtual clinic, we notice a reduction in all key met-
rics, e.g., number of follow-ups (from 726 to 642), and
clinic session utilisation (71% to 64%). The model has in-
cluded all costing and resourcing of running the virtual
clinic. We also experimented where T&E is considered
without the virtual clinic (third column). As expected,
there is a sharp increase in the number of follow-ups,
number of Anti-VEGF injections, and utilisation of re-
sources. For instance, clinic and nurse utilisations has
increased to a critical level of 85%, and without add-
itional staff the system may not be able to cope with a
slight increase in new attendances. This may not be a vi-
able option, clearly showcasing the need to test the sys-
tem with a combination of virtual clinics and T&E
regime.
The fourth column shows the efficiencies generated
comparing the current service against the combination
of virtual clinics and T&E. A T&E regime in combin-
ation with a virtual clinic did not result in an increase in
staff utilisation, but provided a noticeable increase in
capacity with a 10% surplus. This provided the oppor-
tunity for investment in the service, with the increase in
the quality of treatment and improvement in patient
outcomes.
Discussion
The ever increasing demand in medical retinal services
following the introduction of new therapies has resulted
Table 2 The average number of intravitreal injections and FU assessments over the 3 year data period
AMD DR MR
Year of treatment Year of treatment Year of treatment
Year
1
Year
2
Year
3
Year
1
Year
2
Year
3
Year
1
Year
2
Year
3
Average no. of intravitreal injections 4 3 2.5 3.5 2.6 2.6 4 2.8 2.4
Average no. of FU assessments for injected patients 4.8 4 3.6 3.3 3.1 3.6 3.7 3.1 2.5
Average no. of FU assessments for non-treated patients (i.e. observations
only)
1.7 1.6 1.4 1.4 1.4 1.2 1.4 1.4 1.1
Table 3 The number of discharged patients whether in
treatment or under observation over 36 month’s data period
broken down by patient type
In treatment Under observation Total
Number of discharged patients at the end of Year 1 of treatment
AMD 12 147 159
DR 1 330 331
MR 13 611 624
Number of discharged patients at the end of Year 2 of treatment
AMD 16 14 30
DR 5 32 37
MR 13 58 71
Number of discharged patients at the end of Year 3 of treatment
AMD 10 10 20
DR 1 24 25
MR 4 23 27
Total discharges 75 (1%) 1249 (19%) 1324 (20%)
Total non-discharges 950 (15%) 4256 (65%) 5206 (80%)
Total 1025 (16%) 5505 (84%) 6530 (100%)
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in serious capacity constraints, such that some NHS
clinics are failing to maintain the recommended
follow-up/treatment intervals. This may have an increased
risk of permanent vision loss, with huge impact on inde-
pendence and quality of life of patients. It is, therefore, clear
that robust and long term retinal service models that do not
compromise visual outcomes, such as T&E in combination
with virtual clinics, are required across NHS clinics in order
to meet the needs of local populations currently and in the
future. Such long-term management strategy of retinal dis-
ease in virtual clinics has been employed by a number
Trusts in the UK and proven to be safe and effective if
properly implemented [18].
The developed model is a new tool for forecasting and
planning to support decision making in ophthalmology
services. Using patient level data relating to the service,
in conjunction with forecasting and simulation, enables
a Trust to confidently predict the impact of making
changes within the service. The flexibility of the model
enables the impact of a wide range of scenarios to be
tested (around several thousand scenarios can be tested).
A potential solution (T&E in combination with virtual
clinic) is presented here that is shown to improve qual-
ity, effectiveness and productivity and thus increase cap-
acity. Despite the increase in the number of injections
(with T&E), the impact on resource utilisation is negli-
gible (almost 0%) and in some cases below 0%.
Spreadsheet based models commonly use averages, for
example the average number of patients expected each
day followed by the average number of patients who will
be diagnosed with nAMD followed by the average num-
ber of injections in the first year. The problem with
using averages in this way may lead to wildly incorrect
predictions, commonly known as the ‘error of averages’
(Salvage, 2009) [21]. Arguably when considering services
that have a turnover of many millions of pounds it is
very important to be accurate.
Unlike spreadsheet models, the power of discrete
event simulation in general is the ability to capture vari-
ability. For example, some guidelines assume that
anti-VEGF treatments are injected on average of 7 times
in the first year, although patient level data analysis in
this study showed that there were 1–14 intravitreal in-
jections in a year with significantly lower averages. As
such assuming that all patients received an average of 7
injections per year could be misleading.
The choice of using simulation methods as opposed to
analytical methods was partly dictated by the complexity
of the pathway and the ease of use for end-users. In this
respect, the need to track individual patient journeys (or
trajectories) through the care system, the ability to cap-
ture the complex web of interactions of patients going
through the diagnosis stage to various forms of treat-
ment (including FUs) and the need to model notions of
limited availability of resources (such as staff, beds,
rooms and equipment) have motivated us to select
discrete event simulation.
Instead of using averages our model uses each hospital
Trusts’ anonymised patient level data to track individual
patients over a 36-month period. It counts the number
of times a patient is treated and assessed in years 1, 2
and 3. It then uses statistical algorithms to establish the
distribution, for example, treatment frequency for each
year, for example log normal distribution with a mean
and SD. The model is then run hundreds of times for
thousands of patients where the distribution determines
the number of times a patient is injected, as opposed to
using an average of 7 injections per year for each patient.
It is because the model pays close attention to these de-
tails, that it is able to create validated reports that are up
to 95% accurate.
A constraint on modelling analysis is the recognition
of essential resources that are required in order for an
event to happen. For example, it is not possible for a
Table 4 The impact of current service against the combination of virtual clinics and treat and extend
Monthly averages Current
Service
Virtual Clinic + no change in current
service
Treat and Extend + no virtual
clinic
Virtual Clinic + Treat and
Extend
%
change
New attendances 119 119 119 119 0%
Follow-ups 726 642 812 708 −2%
Clinic session utilisation 71% 64% 85% 71% 0%
Nurse utilisation 71% 65% 82% 70% −1%
Consultation room
utilisation
53% 48% 55% 51% −4%
Injection bed utilisation 29% 30% 40% 37% 28%
Number of Anti-VEGF
injections
169 172 218 215 27%
Costing £151,760 £153,963 £192,902 £190,200 25%
Revenue £207,494 £207,494 £260,809 £251,664 21%
Surplus £55,735 £53,532 £67,906 £61,464 10%
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clinic to start without a clinician. The model only starts
a clinic when all the resources required are available. In-
travitreal services are complex with many hundreds of
variables/constraints. The ability to deal with these com-
plex constraints simply does not exist in excel or any other
modelling approaches. Using the model it is possible to
show what happens if there is a variation in the availability
of resources/constraints such as the increase or reduction
in the number of clinic rooms available, or the effect of an
absent clinician. Given the level of complexity and value
of intravitreal services, it is extremely important to ensure
that model outputs are robust and accurate.
The National Institute for Health and Care Excellence
(NICE) has recognised the methodology used in the
model as a valid way of simulating complex patient path-
ways [22]. To the best of our knowledge, this model is
currently the only simulation based planning tool for
retinal service managers. Other such programmes or fur-
ther development would be welcome.
Re-design of clinical services based on such pro-
grammes, nevertheless, requires investment, although
such investment is outweighed by the potential increases
in surplus generated from efficient service re-design. More
importantly, optimum service re-design also leads to bet-
ter quality of care that meet patients’ needs, as well in-
creased productivity by maximising the use of experienced
clinicians. Furthermore, significant cost reductions are ex-
pected in the long-term as more patients retain their vi-
sion with better clinical outcomes due to the T&E or
other similar regimen.
The authors are aware of the many difficulties that are
faced in the planning, approval, and implementation of
new retinal services. Changes can be introduced without
proper consideration of the impact on the service, and
as a result most business cases are inaccurate [12]. Fre-
quently clinicians working within retinal services know
how they would like to improve the service they deliver,
but lack the expertise to frame those improvements in a
manner that is acceptable to health service executives
and managers who hold finance budget. The model was
developed in conjunction with retinal specialists, specif-
ically to address these issues. It is designed to allow
‘non-experts’ to test change on the pathway within the
validated simulation. The simulation will present the im-
pact of changes in a way that can be easily understood
by both the healthcare executives and the pathway spe-
cialists. The intention is that this tool will facilitate ser-
vice planning and decision making and speed up the
pace of change in the retinal pathway.
The tool allows decision makers to develop a bet-
ter understanding of key performance metrics associ-
ated with activity, cost implications and resource
utilisation. The ease of use of the tool with relevant
sets of exported results means that senior decision
makers can be more proactive and confident with
evidence based approach in re-designing their care
pathway in finding the most efficient and effective
delivery of care to patients with problems in the eye.
Conclusions
In conclusion, the model allows the use of pathway plan-
ning to improve clinic efficiency and patient outcomes
without necessarily increasing costs in the long-term.
Additional file
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the value entered in the model. (DOCX 19 kb)
Abbreviations
A&E: Accident & Emergency; AMD: Age Related Macular Degeneration;
anti-VEGF: anti-Vascular Endothelial Growth Factor; DNA: Did Not Attend;
DR: Diabetic Retinopathy; FU: Follow-up; GP: General Practitioner;
MR: Medical Retina; nAMD: neovascular Age Related Macular
Degeneration; NHS: National Health Service; NICE: National Institute for
Health and Care Excellence; PRN: Pro Re Nata; RVO: Retinal Vein
Occlusion; SD-OCT: Spectral Domain Optical Coherence Tomography;
T&E: Treat & Extend
Acknowledgements
We would thank Allergan and the following Retinal Service nurses for their
invaluable input towards establishing the retinal service pathway: Pam Kaur,
Derby Hospitals NHS Foundation Trust; Julie Mitchell, James Paget University
Hospitals NHS Foundation Trust; Anita Wyborn, Maidstone & Tunbridge Wells
NHS Trust; Valerie Mooring, York Hospital NHS Foundation; Tracey Allen,
University Hospitals Birmingham NHS Foundation, and Androulla Antoniou,
Moorfields Eye Hospital NHS Trust.
Availability of data and materials
The data entered in the model is included in the additional file “BMC Health
Services Research paper additional file data for the model”, which has been
submitted with the paper. The National Tariff Payment System, NICE and
MIMs data used to estimate some of the parameters in the model are
publicly available. The links to the website and the date when it was
accessed are available on the list of references of the paper (Reference
numbers [20, 23, 24]). The dataset provided by Cambridge University
Hospitals NHS Foundation Trust, which was used to estimate some of the
parameters for the model, is held in the computer of one of the authors. It
cannot be made publicly available as this is one of the conditions of
acquiring the dataset. In addition, the data is not readable and needs
database programming to be extracted, hence it cannot be made accessible.
Authors’ contributions
ED and DS conceptualise and developed the DES model. ED and WA wrote
the paper with the contribution of DS and AV. All authors agreed on the
final version of the paper. All authors read and approved the final
manuscript.
Ethics approval and consent to participate
Ethics approval and participant consent was not necessary as this study
involved the use of the national Hospital Episodes Statistics (HES) dataset.
Details about HES can be obtained at http://content.digital.nhs.uk/hes. In
addition, the data collection for this study did not require ethics approval as:
a) derived from secondary sources which are clearly set out in the paper, b)
did not include any patient level identifiable data, c) did not include any
patient/public participants, d) the study is categorized as a service evaluation
using a consultation approach. The consultants, nurses and service managers
involved in the research opted to participate. The interviews were not
mandatory. Verbal consent was sought from the consultants, nurses and
Demir et al. BMC Health Services Research  (2018) 18:759 Page 7 of 8
service managers, where participants had given full consent. As stated in
Declarations section, UK ethical approval is not a compulsory requirement
for studies which do not involve patients (see the following link for details
http://www.hra.nhs.uk/documents/2013/09/does-my-project-require-rec-
review.pdf).
Consent for publication
Not applicable.
Competing interests
David Southern is an employee of Pathway Communications. No conflicting
relationship exists for the other authors regarding this article.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1University of Hertfordshire, Hertfordshire Business School, Hertfordshire, UK.
2Pathway Communications Ltd, Cambridge, UK. 3Cambridge University
Hospitals NHS Foundation Trust, Cambridge, UK. 4Academic Ophthalmology,
DCN, Faculty of Medicine, The University of Nottingham, Nottingham, UK.
Received: 20 June 2017 Accepted: 24 September 2018
References
1. UK Vision Strategy 2013–18. 2013. https://www.visionuk.org.uk/refreshed-uk-
vision-strategy-2013-18/. Accessed 14 Nov 2014.
2. Owen CG, Jarrar Z, Wormald R, Cook DG. The estimated prevalence and
incidence of late stage age related macular degeneration in the UK. Br J
Ophthalmol. 2012;96:752–6.
3. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with
intravitreal ranibizumab for neovascular age-related macular degeneration:
year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.
4. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO,
Weichselberger A, Staurenghi G, SUSTAIN Study Group. Safety and efficacy of a
flexible dosing regimen of ranibizumab in neovascular age-related macular
degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71.
5. Haller JA. Current anti-vascular endothelial growth factor dosing regimens:
benefits and burden. Ophthalmology. 2013;120:S3–7.
6. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and
extend regimen using ranibizumab for neovascular age-related macular
degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–40.
7. Rush RB, Simunovic MP, Vandiver L, Aragon AV 2nd, Ysasaga JE. Treat-and-
extend bevacizumab for neovascular age related macular degeneration: the
importance of baseline characteristics. Retina. 2014;34:846–52.
8. Hatz K, Prünte C. Changing from a pro re nata treatment regimen to a treat
and extend regimen with ranibizumab in neovascular age-related macular
degeneration. Br J Ophthalmol. 2016;100:1341–5.
9. Hatz K, Prünte C. Treat and extend versus pro re Nata regimens of
ranibizumab in neovascular age-related macular degeneration: a
comparative 12 month study. Acta Ophtholmol. 2017;95:e67–72.
https://doi.org/10.1111/aos.13031.
10. Kvannli L, Krohn J. Switching from pro re nata to treat-and-extend regimen
improves visual acuity in patients with neovascular age-related macular
degeneration. Acta Ophthalmol. 2017. https://doi.org/10.1111/aos.13356.
11. Danyliv A, Glanville J, McCool R, Ferreira A, Skelly A, Jacob RP. The
clinical effectiveness of Ranibizumab treat and extend regimen in
nAMD: systematic review and network meta-analysis. Adv Ther. 2017.
https://doi.org/10.1007/s12325-017-0484-0.
12. Amoaku W, Blakeney S, Freeman M, Gale R, Johnston R, Kelly SP,
McLaughlan B, Sahu D, Varma D. Action on AMD: Optimising patient
management: act now to ensure current and continual delivery of best
possible patient care. Eye. 2012;26:S1–S21.
13. Karsten K, Fasler K, Charnle A, et al. Implementation of medical retina
virtual clinics in a tertiary eye care referral Centre. Br J Ophthalmol.
2018. https://doi.org/10.1136/bjophthalmol-2017-311494.
14. Trikha S, Macgregor C, Jeffery M, Kirwan J. The Portsmouth based glaucoma
refinement scheme: a role for virtual clinics in the future? Eye. 2012;26:1288–94.
15. Kotecha A, Bonstein K, Cable R, Cammack J, Clipston J, Foster P. Qualitative
investigation of patients’ experience of a glaucoma virtual clinic in a
specialist ophthalmic hospital in London, UK. BMJ Open. 2015;5(12):e009463.
https://doi.org/10.1136/bmjopen-2015-009463.
16. Kotecha A, Baldwin A, Brookes J, Foster PJ. Experiences with developing and
implementing a virtual clinic for glaucoma care in an NHS setting. Clin
Ophthalmol. 2015;9:1915–23.
17. Wright HR, Diamond JP. Service innovation in glaucoma management: using a
web-based electronic patient record to facilitate virtual specialist supervision of
a shared care glaucoma programme. Br J Ophthalmol. 2015;99:313–7.
18. Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J. The concept of
virtual clinics in monitoring patients with age-related macular degeneration.
Acta Ophthalmol. 2016;94:353–5.
19. NHS Improvement (2017). NHS Reference Costs 2017. Retrieved June 13,
2017, from https://improvement.nhs.uk/resources/reference-costs/.
20. NICE (2013). Ranibizumab and Pegaptanib for the treatment of
age-related macular degeneration. Retrieved June 20, 2017, from
https://www.nice.org.uk/guidance/ta155/resources.
21. Salvage S. The flaw of averages: why we underestimate risk in the face of
uncertainty. New Jersey: Wiley; 2009.
22. Davis S, Stevenson M, Tappenden P and Wailoo A. NICE DSU Technical
support document 15: Cost effective modelling using patient level
modelling. 2014. http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD15_
Patientlevel_simulation.pdf. Accessed 1 Sept 2016.
23. Payment by Result (2017). 2016/17 National Tariff Payment System.
Retrieved June 20, 2017, from https://www.gov.uk/government/
publications/nhs-national-tariff-payment-system-201617
24. MIMS. (2017). Prescription drug database. Retrieved June 20, 2017, from
http://www.mims.co.uk/
Demir et al. BMC Health Services Research  (2018) 18:759 Page 8 of 8
